Accepted for Publication: November 28, 2019.
Corresponding Author: Milton Packer, MD, Baylor Scott & White Heart and Vascular Hospital, 621 N Hall St, Dallas, TX 75226 (milton.packer@baylorhealth.edu).
Published Online: February 19, 2020. doi:10.1001/jamacardio.2019.5971
Author Contributions: Dr Grayburn had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Both authors.
Acquisition, analysis, or interpretation of data: Both authors.
Drafting of the manuscript: Packer.
Critical revision of the manuscript for important intellectual content: Both authors.
Statistical analysis: Both authors.
Administrative, technical, or material support: Grayburn.
Conflict of Interest Disclosures: Dr Packer reported receiving personal fees from AbbVie, Akcea, AstraZeneca, Amgen, Actavis, Boehringer, Cardiorentis, Daiichi Sankyo, Johnson & Johnson, Novo Nordisk, Pfizer, Sanofi, Synthetic Biologics, and Theravance outside the submitted work. Dr Grayburn reported receiving grants and personal fees from Abbott Vascular, Edwards Lifesciences, and W. L. Gore; grants from Boston Scientific, Medtronic, NeoChord, and Cardiovalve; and personal fees from 4C Medical during the conduct of the study.
Additional Information: The analyses of the Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation (COAPT) subgroups have been publicly presented, have been included in regulatory submissions by the sponsor of the COAPT trial (Abbott), and were confirmed and expanded by Maria Alu, BA, of the Cardiovascular Research Foundation, New York, NY. No compensation outside of salary was provided.
1.Nasser
R , Van Assche
L , Vorlat
A ,
et al. Evolution of functional mitral regurgitation and prognosis in medically managed heart failure patients with reduced ejection fraction.
JACC Heart Fail. 2017;5(9):652-659. doi:
10.1016/j.jchf.2017.06.015
PubMedGoogle ScholarCrossref 2.Bandera
F , Generati
G , Pellegrino
M ,
et al. Mitral regurgitation in heart failure: insights from CPET combined with exercise echocardiography.
Eur Heart J Cardiovasc Imaging. 2017;18(3):296-303. doi:
10.1093/ehjci/jew096PubMedGoogle Scholar 8.De Maria
R , Gavazzi
A , Caroli
A , Ometto
R , Biagini
A , Camerini
F ; Italian Multicenter Cardiomyopathy Study (SPIC) Group. Ventricular arrhythmias in dilated cardiomyopathy as an independent prognostic hallmark.
Am J Cardiol. 1992;69(17):1451-1457. doi:
10.1016/0002-9149(92)90900-J
PubMedGoogle ScholarCrossref 10.Grayburn
PA , Sannino
A , Packer
M . Proportionate and disproportionate functional mitral regurgitation: a new conceptual framework that reconciles the results of the MITRA-FR and COAPT trials.
JACC Cardiovasc Imaging. 2019;12(2):353-362. doi:
10.1016/j.jcmg.2018.11.006
PubMedGoogle ScholarCrossref 17.Bartko
PE , Arfsten
H , Heitzinger
G ,
et al. Papillary muscle dyssynchrony-mediated functional mitral regurgitation: mechanistic insights and modulation by cardiac resynchronization.
JACC Cardiovasc Imaging. 2019;12(9):1728-1737. doi:
10.1016/j.jcmg.2018.06.013
PubMedGoogle ScholarCrossref 18.Ypenburg
C , Lancellotti
P , Tops
LF ,
et al. Acute effects of initiation and withdrawal of cardiac resynchronization therapy on papillary muscle dyssynchrony and mitral regurgitation.
J Am Coll Cardiol. 2007;50(21):2071-2077. doi:
10.1016/j.jacc.2007.08.019
PubMedGoogle ScholarCrossref 19.Kanzaki
H , Bazaz
R , Schwartzman
D , Dohi
K , Sade
LE , Gorcsan
J
III . A mechanism for immediate reduction in mitral regurgitation after cardiac resynchronization therapy: insights from mechanical activation strain mapping.
J Am Coll Cardiol. 2004;44(8):1619-1625. doi:
10.1016/j.jacc.2004.07.036
PubMedGoogle ScholarCrossref 20.Brandt
RR , Reiner
C , Arnold
R , Sperzel
J , Pitschner
HF , Hamm
CW . Contractile response and mitral regurgitation after temporary interruption of long-term cardiac resynchronization therapy.
Eur Heart J. 2006;27(2):187-192. doi:
10.1093/eurheartj/ehi558
PubMedGoogle ScholarCrossref 21.Kato
S , Nakamori
S , Roujol
S ,
et al. Relationship between native papillary muscle T
1 time and severity of functional mitral regurgitation in patients with non-ischemic dilated cardiomyopathy.
J Cardiovasc Magn Reson. 2016;18(1):79. doi:
10.1186/s12968-016-0301-y
PubMedGoogle ScholarCrossref 22.Konstantinou
DM , Papadopoulou
K , Giannakoulas
G ,
et al. Determinants of functional mitral regurgitation severity in patients with ischemic cardiomyopathy versus nonischemic dilated cardiomyopathy.
Echocardiography. 2014;31(1):21-28. doi:
10.1111/echo.12304
PubMedGoogle ScholarCrossref 23.Flynn
M , Curtin
R , Nowicki
ER ,
et al. Regional wall motion abnormalities and scarring in severe functional ischemic mitral regurgitation: a pilot cardiovascular magnetic resonance imaging study.
J Thorac Cardiovasc Surg. 2009;137(5):1063-1070.e2. doi:
10.1016/j.jtcvs.2008.12.023
PubMedGoogle ScholarCrossref 24.Mihos
CG , Yucel
E , Capoulade
R ,
et al. Effects of cardiac resynchronization therapy after inferior myocardial infarction on secondary mitral regurgitation and mitral valve geometry.
Pacing Clin Electrophysiol. 2018;41(2):114-121. doi:
10.1111/pace.13255
PubMedGoogle ScholarCrossref 25.Braun
J , Bax
JJ , Versteegh
MIM ,
et al. Preoperative left ventricular dimensions predict reverse remodeling following restrictive mitral annuloplasty in ischemic mitral regurgitation.
Eur J Cardiothorac Surg. 2005;27(5):847-853. doi:
10.1016/j.ejcts.2004.12.031
PubMedGoogle ScholarCrossref 27.Nishimura
RA , Otto
CM , Bonow
RO ,
et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
J Am Coll Cardiol. 2017;70(2):252-289. doi:
10.1016/j.jacc.2017.03.011
PubMedGoogle ScholarCrossref 28.Vahanian
A , Alfieri
O , Andreotti
F ,
et al; ESC Committee for Practice Guidelines (CPG); Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC); European Association for Cardio-Thoracic Surgery (EACTS). Guidelines on the management of valvular heart disease (version 2012): the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS).
Eur J Cardiothorac Surg. 2012;42(4):S1-S44. doi:
10.1093/ejcts/ezs455
PubMedGoogle ScholarCrossref 29.Biner
S , Rafique
A , Rafii
F ,
et al. Reproducibility of proximal isovelocity surface area, vena contracta, and regurgitant jet area for assessment of mitral regurgitation severity.
JACC Cardiovasc Imaging. 2010;3(3):235-243. doi:
10.1016/j.jcmg.2009.09.029
PubMedGoogle ScholarCrossref 39.Gelsomino
S , Lorusso
R , De Cicco
G ,
et al. Five-year echocardiographic results of combined undersized mitral ring annuloplasty and coronary artery bypass grafting for chronic ischaemic mitral regurgitation.
Eur Heart J. 2008;29(2):231-240. doi:
10.1093/eurheartj/ehm468
PubMedGoogle ScholarCrossref 40.Grossi
EA , Woo
YJ , Patel
N ,
et al. Outcomes of coronary artery bypass grafting and reduction annuloplasty for functional ischemic mitral regurgitation: a prospective multicenter study (Randomized Evaluation of a Surgical Treatment for Off-Pump Repair of the Mitral Valve).
J Thorac Cardiovasc Surg. 2011;141(1):91-97. doi:
10.1016/j.jtcvs.2010.08.057
PubMedGoogle ScholarCrossref 45.Senni
M , Adamo
M , Metra
M , Alfieri
O , Vahanian
A . Treatment of functional mitral regurgitation in chronic heart failure: can we get a “proof of concept” from the MITRA-FR and COAPT trials?
Eur J Heart Fail. 2019;21(7):852-861. doi:
10.1002/ejhf.1491
PubMedGoogle ScholarCrossref